QUEBEC CITY, Quebec – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for 2019. Highlights For the Quarter and The Year Record consolidated revenues at $32.8 M for FY2019 compared with $24.1 M for FY2018, a 36% increase; Fractional Flow …
Latest News From Lumira Ventures
Aurinia Appoints Sr. Finance Executive to Board of Directors
VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the appointment of Ms. Jill Leversage to …
Satsuma Pharmaceuticals Releases Q3 2019 Financial & Business Results
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended September 30, 2019 and provided a business update on recent achievements. “With the …
Forbius Completes Phase 1 Oncology Dose Escalation with AVID200
Austin, TX, and Montreal, QC (Nov. 8, 2019) – Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today presented the first Phase 1 clinical data from its oncology development program with AVID200, in a late-breaking …
First Clinical Use of the OptoWire III following Health Canada Approval
QUEBEC CITY, QUEBEC – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today announced the world’s first clinical use of the OptoWire III, following the recent Health Canada approval. “This improved version of OptoWire for physiological measurement offers maneuverability and …
Aurinia Pharmaceuticals Completes Voclosporin Study
VICTORIA, British Columbia — (BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the completion of a FDA-requested clinical …
Opsens Expands Medical Device Business into Structural Cardiology Market
QUEBEC CITY / CNW Telbec/ –Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) announces today it is expanding its medical device business into the structural cardiology space and will accelerate development activities of products that reach beyond its current coronary and peripheral applications. …
Zymeworks Reports Q3 2019 Financial Results
“We recently presented data on our lead asset, ZW25, at two major medical conferences that pave the way for registration-enabling trials in second-line biliary tract cancer (BTC) with single agent ZW25 and in first-line gastroesophageal adenocarcinoma (GEA) with ZW25 in …
G1 Therapeutics Reports Q3 2019 Financials
RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2019. Review the full filling here. “Based on written feedback from the FDA following our pre-NDA meeting …
Notch Therapeutics Announces R&D Collaboration with Allogene worth up to $283M per Target
SOUTH SAN FRANCISCO, Calif. and TORONTO — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, …
Lumira Joins Financing Syndicate for Notch Therapeutics – a New Company with Revolutionary Allogeneic T Cell Technology
Toronto, ON, (GLOBE NEWSWIRE) — Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, …
Aurinia Initiates Patient Dosing in Dry Eye Syndrome Clinical Trial
VICTORIA, British Columbia — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced the initiation of patient dosing in the Phase …
Zymeworks Releases Phase 1 Data for ZW25 at International Conference
BOSTON — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announces the first data from its Phase 1 study evaluating novel bispecific antibody ZW25 in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma (GEA) in a poster …
Bardy Diagnostics Wins Digital Health Pitch Session at ESC Congress 2019
SEATTLE /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that it was selected as winner of the “Remote Monitoring in Arrhythmias” Technology and Innovation Pitch Session held as part …
Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study
TORONTO / Accesswire / – Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the Company’s lead product candidate, EB01, as a monotherapy for …